NCT05052801 2026-02-19
FORTITUDE-101
Amgen
Phase 3 Active not recruiting
Clinical Trials
6 trialsNCT05111626 2025-12-15
FORTITUDE-102
Amgen
Phase 3 Active not recruiting
NCT05322577 2025-12-05
FORTITUDE-103
Amgen
Phase 1/2 Active not recruiting
NCT02318329 2024-06-04
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
Five Prime Therapeutics, Inc.
Phase 1 Completed
NCT03343301 2024-02-28
FIGHT
Five Prime Therapeutics, Inc.
Phase 1 Completed
NCT03694522 2024-02-28
FIGHT
Five Prime Therapeutics, Inc.
Phase 2 Completed